4-Ethoxy-7,9-dimethyl-8-(4-nitrobenzyl)-2-piperazin-1-yl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine → 8-(4-Aminobenzyl)-4-ethoxy-7,9-dimethyl-2-piperazin-1-yl-pyrido[3',2':4,5]thieno[3,2-d]pyrimidine
反応式
[OH-].[NH3+]N.[CH2:4]([O:6][C:7]1[C:8]2[S:21][C:20]3[N:22]=[C:23]([CH3:37])[C:24]([CH2:27][C:28]4[CH:33]=[CH:32][C:31]([N+:34]([O-])=O)=[CH:30][CH:29]=4)=[C:25]([CH3:26])[C:19]=3[C:9]=2[N:10]=[C:11]([N:13]2[CH2:18][CH2:17][NH:16][CH2:15][CH2:14]2)[N:12]=1)[CH3:5]>C(O)C.[Pd]>[NH2:34][C:31]1[CH:32]=[CH:33][C:28]([CH2:27][C:24]2[C:23]([CH3:37])=[N:22][C:20]3[S:21][C:8]4[C:7]([O:6][CH2:4][CH3:5])=[N:12][C:11]([N:13]5[CH2:18][CH2:17][NH:16][CH2:15][CH2:14]5)=[N:10][C:9]=4[C:19]=3[C:25]=2[CH3:26])=[CH:29][CH:30]=1参加物
5
反応物 2
生成物 1
試薬・触媒・溶媒 2
実験手順
40 mg 10% Pd/C and 0.5 ml (10 mmol) hydraziniumhydroxide are added to 0.36 g (0.8 mmol) 4-ethoxy-7,9-dimethyl-8-(4-nitrobenzyl)-2-piperazin-1-yl-pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine in 3 ml ethanol. Then, refluxing is carried for 10 h, the solvent is removed and the residue is taken up with 50 ml chloroform. Following filtration, the solvent is removed and the residue is recrystallized from chloroform/cyclohexane. 0.16 g (45%) of the title substance is obtained.
後処理
- temperatureThen, refluxing
- customthe solvent is removed
- filtrationfiltration
- customthe solvent is removed
- customthe residue is recrystallized from chloroform/cyclohexane
- custom0.16 g (45%) of the title substance is obtained
出典と根拠
- ORDレコード
- ord-a2020dcb98cf4e7abd4ee502d174d483
- 出典データセット
- uspto-grants-2011_11
- 特許番号
- US08058285B2
反応ノート
読み込み中…